A1 Refereed original research article in a scientific journal

The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death




AuthorsYan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M

PublisherAMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC

Publication year2003

Journal:Journal of Biological Chemistry

Journal name in sourceJOURNAL OF BIOLOGICAL CHEMISTRY

Journal acronymJ BIOL CHEM

Volume278

Issue46

First page 45358

Last page45367

Number of pages10

ISSN0021-9258

DOIhttps://doi.org/10.1074/jbc.M307933200


Abstract
Hematopoietic growth factors mediate the survival and proliferation of blood-forming cells, but the mechanisms through which these proteins produce their effects are incompletely known. Recent studies have identified the pim family of kinases as mediators of cytokine-dependent survival signals. Several studies have identified substrates for the pim-1 kinase, but little is known about the other family members, pim-2 and pim-3. We have investigated potential functions for the pim-2 kinase in factor-dependent murine hematopoietic cells. We find that pim-2 mRNA and protein expression are regulated by cytokines similarly to pim-1. Three PIM-2 protein isoforms are produced in cytokine-treated cells. All three forms are active kinases, and the short (PIM-2(34 kDa)) form is the most active at enhancing survival of FDCP1 cells after cytokine withdrawal. This pro-survival function involves inhibition of apoptosis and caspase activation. Enforced expression of PIM-2 (34 kDa) kinase does not appear to regulate expression of BCL-2, BCL-xL, BIM, or BAX proteins. However, the kinase can phosphorylate the pro-apoptotic protein BAD on serine 112, which accounts in part for its ability to reverse Bad-induced cell death. Our results indicate that pim-2 functions similarly to pim-1 as a pro-survival kinase and suggest that BAD is a legitimate PIM-2 substrate.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2025-14-10 at 09:39